Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vacc… (NCT05450770) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination
60 participantsStarted 2024-11-01
Plain-language summary
ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subjects included in the ANRS EP 46 NOVAA trial:
* 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \> 350/mm3 and a viral load \<50 copies / mL for at least 6 months).
* 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.
* Subjects agreeing to be monitored according to the terms of the protocol.
* Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.
* Signature of informed consent.
Exclusion Criteria:
* Non-volunteers for the 10-year follow-up
* Subject under curatorship, guardianship or safeguard of justice.